Anemia Management in LR-MDS: Treatment Insights From ASH 2024
Thomas W. LeBlanc, MD, MA, discusses how recent updates from the COMMANDS trial and advancements in anemia management, including the role of luspatercept, are shaping the treatment landscape for low-risk myelodysplastic syndromes (LR-MDS) and improving patient outcomes and quality of life.
EP. 1: An Overview of the Treatment Landscape for Anemia Management in LR-MDS
December 20th 2024Thomas W. LeBlanc, MD, MA, discusses how the standard of care (SOC) options for anemia management in patients with low-risk myelodysplastic syndromes (LR-MDS) typically involve erythropoiesis-stimulating agents and transfusion support, with emerging therapies like luspatercept offering new treatment options for better patient outcomes.
Watch
